chemotherapeutic resistance

Show results for

Unknown (3309)
Genomics (326)
Transcriptomics (261)
Proteomics (55)
Other (15)
Clinical (4)
Models (2)
Methylation profiling (2)
Metabolomics (2)

Organisms

Homo sapiens (291)
Aerococcus urinae NBRC 15544 = CCUG 36881 (38)
Andropogon gerardi (38)
Bacteria (38)
Bartonella quintana JK 31 (38)
Canis lupus familiaris (38)
Cnidaria (38)
Ectopseudomonas oleovorans CECT 5344 (38)
Ensifer adhaerens (38)
Halictus scabiosae (38)
Human immunodeficiency virus 1 (38)
Mesocricetus auratus (38)
Miscanthus x giganteus (38)
Mus musculus (38)
Panicum virgatum (38)
Pseudomonas aeruginosa SJTD-1 (38)
Rabies virus Nishigahara RCEH (38)
Rattus norvegicus (38)
Rattus rattus (38)
Mus musculus (35)
Plasmodium falciparum (2)
Cricetulus griseus (2)
synthetic construct (2)
Listeria monocytogenes 10403S (1)
mouse gut metagenome (1)
Mycobacterium tuberculosis H37Rv (1)
Caulobacter vibrioides NA1000 (1)
Drosophila melanogaster (1)
Fusobacterium nucleatum (1)
Acyrthosiphon pisum (1)

Organisms

Homo sapiens (218)
Mus musculus (27)
Fusobacterium nucleatum (1)
Mycobacterium tuberculosis variant bovis BCG (1)
Cricetulus griseus (1)
Drosophila melanogaster (1)
Plasmodium falciparum (1)
Mycobacterium tuberculosis (1)
Escherichia coli (1)

Repository

ENA (285)
geo (229)
biostudies-arrayexpress (83)
pride (38)
jPOST (9)
EGA (7)
iProX (6)
BioModels (2)
MassIVE (2)
MetaboLights (2)

Tissue

Cell culture (19)
Epithelial cell (5)
Permanent cell line cell (5)
Colon (2)
Pancreatic ductal adenocarcinoma cell line (2)
Blood (1)
Brain (1)
Breast cancer cell line (1)
Embryonic stem cell (1)
Endothelial cell (1)
Fibroblast (1)
Glioblast (1)
Hepatocyte (1)
Kidney (1)
Leukocyte (1)
Neuroblastoma cell (1)
Neuroblastoma cell line (1)
Ovarian surface epithelial cell (1)
Pancreatic duct (1)
Pancreatic ductal cell (1)
Pancreatic stellate cell (1)
Pharynx (1)
Trophozoite (1)

Disease

Colorectal Neoplasms (4)
Colon cancer (4)
Acute leukemia (3)
Breast cancer (3)
Malignant neoplasm of ovary (3)
Glioblastoma (2)
Hepatocellular carcinoma (2)
Ovarian cancer patient invasive malignant (1)
Fibrosarcoma (1)
Brain glioblastoma multiforme (1)
Disease free (1)
Giardiasis (1)
Head and neck squamous cell carcinoma (1)
Neuroblastoma (1)
Pancreas adenocarcinoma (1)
Pancreatic ductal carcinoma (1)

Technology Type

Mass Spectrometry (38)
Shotgun proteomics (27)
Bottom-up proteomics (6)
Affinity purification coupled with mass spectrometry proteomics (5)
Gel-based experiment (4)
Mass spectrometry (2)
All-ion fragmentation (2)
Chemical cross-linking coupled with mass spectrometry proteomics (2)
Data-dependent acquisition (2)
SWATH MS (2)
HiSeq X Ten, ILLUMINA, Illumina HiSeq 2500 (1)
Illumina HiSeq 2000 (1)
Affinity proteomics (1)
Data-independent acquisition (1)
HDMSE (1)
MSE (1)
Mass spectrometry imaging (1)
PAcIFIC (1)
RNA mass spectrometry (1)
SRM/MRM (1)

Instrument Platform

Illumina HiSeq 2500 (3)
Illumina NovaSeq 6000 (2)
Liquid Chromatography MS - negative - reverse phase (2)
Liquid Chromatography MS - positive - reverse phase (2)
TBS380 (1)
Nanodrop2000 (1)
NA (1)
LTQ Orbitrap (1)
Orbitrap Exploris 480 (1)

Publication Date

2026 (49)
2025 (48)
2021 (33)
2024 (31)
2022 (21)
2015 (17)
2023 (17)
2020 (16)
2016 (16)
2011 (16)
2010 (16)
2019 (15)
2018 (14)
2013 (14)
2014 (11)
2017 (9)
2008 (9)
2012 (7)
2007 (5)
2009 (3)
2006 (1)

CHEBI ID

CHEBI:71201 (1)
CHEBI:36559 (1)
CHEBI:16300 (1)
CHEBI:32544 (1)
CHEBI:16675 (1)
CHEBI:995 (1)
CHEBI:15763 (1)
CHEBI:17154 (1)
CHEBI:15927 (1)
CHEBI:16171 (1)
CHEBI:18361 (1)
CHEBI:18344 (1)
CHEBI:16828 (1)
CHEBI:17380 (1)
CHEBI:30249 (1)
CHEBI:18304 (1)
CHEBI:16946 (1)
CHEBI:16960 (1)
CHEBI:15379 (1)
CHEBI:18050 (1)
CHEBI:17111 (1)
CHEBI:18009 (1)
CHEBI:16474 (1)
CHEBI:15846 (1)
CHEBI:16134 (1)
CHEBI:16027 (1)
CHEBI:18367 (1)
CHEBI:16761 (1)
CHEBI:15422 (1)
CHEBI:16467 (1)

Metabolite Name

Thiamine(1+) diphosphate (1)
9,10,18-trihydroxyoctadecanoic acid (1)
Ceramide phosphoethanolamine (d31:0) (1)
Ceramide phosphoethanolamine (t35:0) (1)
1-octadecyl-sn-glycero-3-phosphoinositol-3-phosphate (1)
Phosphatidylinositol (12:0) (1)
PA(15:0/20:2(11Z,14Z)) (1)
18-hydroxycorticosterone (1)
2-hydroxyoctanoic acid (1)
11-dehydrocorticosterone (1)
PA(20:2(11Z,14Z)/15:0) (1)
9,10,13-Trihydroxystearic acid (1)
Aldosterone (1)
Ubiquinone-1 (1)

First Public Date

2026 (59)
2025 (43)
2021 (30)
2024 (28)
2014 (27)
2022 (18)
2023 (15)
2020 (15)
2019 (15)
2017 (11)
2018 (9)
2015 (7)
2016 (5)
2013 (3)

Modelling Approach

Constraint-based model (1)
Ordinary differential equation model (1)

Study status

Recruiting (2)
Completed (2)

Lab affiliation

The Second Hospital of Dalian Medical University (3)
Institute of Molecular Biology (IMB), Mainz, Germany (2)
1 - College of Pharmacy, University of Sharjah, Sharjah 2 - Sharjah Institute for Medical Research, University of Sharjah, Sharjah (1)
Baker Heart & Diabetes Inst. (1)
Biomedical Research in Cancer Stem Cells Group,Pathology Department, Collserola Building, Lab 205,Vall d'Hebron Research Institute (VHIR, Passeig Vall d'Hebron 119-129,Barcelona 08035, Spain. Tel: +34-93-489-4169 FAX: +34-93-274-6708 (1)
Cell Signalling & Proteomics Group, Barts Cancer Institue, Queen Mary University of London, London, UK (1)
Center for Bioanalysis, Division of Chemical and Medical Metrology, Korea Research Institute of Standards and Science, Daejeon 34113, Republic of Korea (1)
Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London (1)
Centre for Genomics and Computational Biology, Barts Cancer Institute, Queen Mary Universty of London (1)
Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA (1)
Department of Biology II and Center for Integrated Protein Science Munich (CIPSM), Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany (1)
Department of Chemistry and Biochemistry, The Ohio State University, Columbus, Ohio 43210, United States (1)
Department of Experimental Neurodegeneration, University Medical Center Goettingen (1)
Department of Pediatric Hematology and Oncology, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany (1)
Experimental Neurosurgery, University Hospital,Goethe University, Frankfurt, Germany (1)
Functional Proteomics, ICR (1)
Georgetown University Medical Center (1)
IMB, Ackermannweg 4, 55128 Mainz (1)
Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt am Main, Germany Frankfurt Cancer Institute, Frankfurt am Main, Germany Cardio-Pulmonary Institute, Frankfurt am Main, Germany (1)
Laboratory of Proteomics, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences (1)
Ludwig-Maximilians-Universität München Genzentrum Laboratory for Functional Genome Analysis Feodor-Lynen-Str. 25 D-81377 München (1)
MaP, Marseille Proteomique Centre de Recherche en Cancérologie de Marseille INSERM U1068/Institut Paoli-Calmettes 27, Bd Leï Roure, BP30059, 13273 Marseille CEDEX 9, France (1)
Max-Planck-Institute for Biology of Ageing Department of Mitochondrial Proteostasis Joseph-Stelzmann-Str. 9b 50931 Cologne (1)
NICM, Western Sydney University Faculty of pharmacy Cairo University (1)
Penengo Lab, Institute of Molecular Cancer Research, University of Zurich, Switzerland (1)
Population Health and Immunity, Walter and Eliza Hall Institute of Medical Research (1)
Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital (1)
Proteomics center, Erasmus MC (1)
Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK. UCL Cancer Institute, University College London, London, United Kingdom. Cancer Research UK City of London Centre. GSK (1)
School of Biomedical Sciences, The Chinese University of Hong Kong (1)

Keyword

Genistein (1)
Soy supplements (1)
Phytoestrogens (1)
FOLFOX-Avastin (1)
Muscle strength (1)
Cardiorespiratory fitness (1)
Chemotherapy dose modification (1)
Bayesian adaptive trial (1)
Progression free survival (1)
MGMT (1)
Microsatellite stable (1)
First-line (1)
Stage IV (1)
Phase 1 (1)
Temozolomide (1)
Gemcitabine (1)
FOLFOX (1)
Chemotherapy (1)
Metastatic (1)
Irinotecan (1)
Exercise (1)
Leucovorin (1)
Bevacizumab (1)
Fluorouracil (1)

IsPrivate

False (2)

Model Flag

Non Kinetic (1)

Classification

bacteria (4)
protozoa (1)

Study type

Transcription profiling by array (67)
RNA-seq of coding RNA (5)
Interventional (4)
Methylation profiling by array (3)
Comparative genomic hybridization by array (2)
ChIP-chip by tiling array (1)
ChIP-seq (1)
DNA-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)
RNA-seq of non coding RNA (1)

Release Date

2021 (365)
2022 (352)
2020 (305)
2023 (297)
2024 (270)
2025 (259)
2019 (238)
2018 (210)
2017 (208)
2016 (197)
2014 (132)
2015 (128)
2013 (85)
2012 (80)
2011 (63)
2010 (55)
2008 (35)
2026 (35)
2009 (34)
2007 (10)
2006 (9)
2005 (7)
2003 (6)
2004 (3)
2001 (3)
1997 (2)
2002 (1)
1999 (1)
1998 (1)

Location

Italy (1)
Netherlands (1)
United States (1)
South Korea (1)

Previous page
1 / 398
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 398
Next page

Sort by:

Relevance

Page size

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [CUT&Run]

PRJNA1220705 | ENA

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [RNA-Seq]

PRJNA1220703 | ENA

Pharmacogenomic Approach for the Identification of Novel Determinants of Resistance to Oxaliplatin in Colon Cancer

Oxaliplatin is a member of the family of Pt-containing chemotherapeutic agents that also include cisplatin (CDDP) and carboplatin. OXA is distinguished from these two older drugs by its different spectrum of activity both in preclinical models and in clinical trials. It is the only platinum analogue...

ORGANISM(S): Homo sapiens

2010-05-26 | E-GEOD-10405 | biostudies-arrayexpress

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [RNA-Seq, 2]

PRJNA1391448 | ENA

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [Cut & Run, 2]

PRJNA1391444 | ENA

Kinesin KIF4A is associated with chemotherapeutic drug resistance by regulating intracellular trafficking of lung resistance-related protein.

Not available

S-EPMC5742287 | biostudies-literature

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [CUT&Run]

Chemotherapy remains one of the most important treatments for lung squamous cell carcinoma (LSCC), yet overcoming chemotherapeutic drug resistance poses a significant challenge. The high frequency of SOX2 copy number amplification observed in LSCC patients underscores its potential role as a regulat...

ORGANISM(S): Homo sapiens

2026-03-14 | GSE289046 | GEO

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [RNA-Seq]

ORGANISM(S): Homo sapiens

2026-03-14 | GSE289045 | GEO

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [RNA-Seq, 2]

ORGANISM(S): Homo sapiens

2026-03-14 | GSE314519 | GEO

Disrupting SOX2 Self-Association and Condensates to Overcome Chemotherapeutic Drug Resistance in Lung Squamous Cell Carcinoma [Cut & Run, 2]

ORGANISM(S): Homo sapiens

2026-03-14 | GSE314516 | GEO

Previous page
1 / 398
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 398
Next page

Sort by:

Relevance

Page size

3976 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Model Flag

Classification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets